These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 25256065)

  • 1. Investigating the immunodominance of carbohydrate antigens in a bivalent unimolecular glycoconjugate vaccine against serogroup A and C meningococcal disease.
    Adamo R; Nilo A; Harfouche C; Brogioni B; Pecetta S; Brogioni G; Balducci E; Pinto V; Filippini S; Mori E; Tontini M; Romano MR; Costantino P; Berti F
    Glycoconj J; 2014 Dec; 31(9):637-47. PubMed ID: 25256065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine.
    Donadei A; Balocchi C; Mancini F; Proietti D; Gallorini S; O'Hagan DT; D'Oro U; Berti F; Baudner BC; Adamo R
    Eur J Pharm Biopharm; 2016 Oct; 107():110-9. PubMed ID: 27388628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM
    Beresford NJ; Martino A; Feavers IM; Corbel MJ; Bai X; Borrow R; Bolgiano B
    Vaccine; 2017 Jun; 35(28):3598-3606. PubMed ID: 28408122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
    de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ
    Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines.
    Buonsanti C; Balocchi C; Harfouche C; Corrente F; Galli Stampino L; Mancini F; Tontini M; Malyala P; Bufali S; Baudner B; De Gregorio E; Valiante NM; O'Hagan DT; Rappuoli R; D'Oro U
    Sci Rep; 2016 Jul; 6():29063. PubMed ID: 27439378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.
    Pecetta S; Lo Surdo P; Tontini M; Proietti D; Zambonelli C; Bottomley MJ; Biagini M; Berti F; Costantino P; Romano MR;
    Vaccine; 2015 Jan; 33(2):314-20. PubMed ID: 25448110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
    van Ravenhorst MB; den Hartog G; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    PLoS One; 2018; 13(4):e0191261. PubMed ID: 29672552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.
    Pajon R; Fergus AM; Granoff DM
    PLoS One; 2013; 8(6):e66536. PubMed ID: 23805230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
    Tunheim G; Naess LM; Acevedo R; Fjeldheim ÅK; Bolstad K; García L; Cardoso D; Aase A; Zayas C; González H; Rosenqvist E; Norheim G
    Vaccine; 2014 Nov; 32(49):6631-8. PubMed ID: 25305564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of a protective epitope reveals the importance of acetylation of
    Henriques P; Dello Iacono L; Gimeno A; Biolchi A; Romano MR; Arda A; Bernardes GJL; Jimenez-Barbero J; Berti F; Rappuoli R; Adamo R
    Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29795-29802. PubMed ID: 33158970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines.
    Tontini M; Berti F; Romano MR; Proietti D; Zambonelli C; Bottomley MJ; De Gregorio E; Del Giudice G; Rappuoli R; Costantino P; ; Brogioni G; Balocchi C; Biancucci M; Malito E
    Vaccine; 2013 Oct; 31(42):4827-33. PubMed ID: 23965218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of meningococcal serogroup C vaccine programmes.
    Borrow R; Abad R; Trotter C; van der Klis FR; Vazquez JA
    Vaccine; 2013 Sep; 31(41):4477-86. PubMed ID: 23933336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.
    Badahdah AM; Rashid H; Khatami A
    Expert Rev Vaccines; 2016; 15(1):9-29. PubMed ID: 26560735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
    Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
    Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
    Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
    Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana.
    Hodgson A; Forgor AA; Chandramohan D; Reed Z; Binka F; Bevilacqua C; Boutriau D; Greenwood B
    PLoS One; 2008 May; 3(5):e2159. PubMed ID: 18478093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein.
    Xu L; Li Z; Su Z; Yang Y; Ma G; Yu R; Zhang S
    Vaccine; 2019 Feb; 37(7):956-964. PubMed ID: 30655174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
    Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
    Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.